Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2026
Management of cervical cancer with lymph nodes involvement in a large tertiary centre: Results from the preimmunotherapy era.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Laurent Delanghe Grégoire, Escande Alexandre, Risbourg Séverine, Sayadi Diane, Noeuvéglise Alexandra, Ben Miled Aïcha, Pasquesoone Camille, Chevalier Hortense, Martinez-Gomez Carlos, Bresson Lucie, Navarro Anne-Sophie, Cayez Romain, Le Deley Marie-Cécile, Narducci Fabrice, Lartigau Éric F, Cordoba Abel
Аннотация
PURPOSE: This study aimed to assess the specific outcomes of patients locally advanced node-positive cervical cancer according to the International Federation of Gynaecology and Obstetrics receiving concurrent chemoradiotherapy and image-guided adaptive brachytherapy before adjuvant immunotherapy.
PATIENTS AND METHODS: A cohort of 388 women with non-metastatic advanced cervical cancer and lymph node involvement treated at a single tertiary centre (2016-2021) was analysed. All patients underwent chemoradiotherapy followed by brachytherapy. Disease-free survival and overall survival were compared between patients with only pelvic node involvement (n=175) and those with at least para-aortic node involvement (n=213), as well as across node staging methods. Notably, some patients also had bladder or rectal involvement.
RESULTS: With a median follow-up of 54.8 months, 152 progressions or recurrences were reported, including metastatic event in 99 cases (65.1 % of first events). Additionally, 22 deaths occurred without previous progression/relapse. This resulted in a 5-year disease-free survival rate of 50.8 % (95 % confidence interval [CI]: 45.2-56.2 %) for the entire cohort, significantly differing between the pelvic (58.5 %; 95 % CI: 50.1-65.9 %) and para-aortic (44.2 %; 95 % CI: 36.7-51.4 %) groups (p=0.007). The 5-year overall survival rate was 61.0 % (95 % CI: 55.7-65.8 %) in the entire cohort and was poorer in patients with para-aortic involvement (52.5 %; 95 % CI: 45.1-59.3 %; p=0.002). A larger high-risk clinical target volume at least 43.5cm3 (p=0.0001), para-aortic node involvement (p=0.01), and a total treatment duration of more than 55 days (p=0.01) were associated with a higher recurrence risk.
CONCLUSION: Chemoradiotherapy followed by brachytherapy is effective and feasible for patients with node-positive cervical cancer. However, two-thirds of progressions or recurrences involved a distant event, suggesting the need to evaluate incremental systemic treatment strategies.
PATIENTS AND METHODS: A cohort of 388 women with non-metastatic advanced cervical cancer and lymph node involvement treated at a single tertiary centre (2016-2021) was analysed. All patients underwent chemoradiotherapy followed by brachytherapy. Disease-free survival and overall survival were compared between patients with only pelvic node involvement (n=175) and those with at least para-aortic node involvement (n=213), as well as across node staging methods. Notably, some patients also had bladder or rectal involvement.
RESULTS: With a median follow-up of 54.8 months, 152 progressions or recurrences were reported, including metastatic event in 99 cases (65.1 % of first events). Additionally, 22 deaths occurred without previous progression/relapse. This resulted in a 5-year disease-free survival rate of 50.8 % (95 % confidence interval [CI]: 45.2-56.2 %) for the entire cohort, significantly differing between the pelvic (58.5 %; 95 % CI: 50.1-65.9 %) and para-aortic (44.2 %; 95 % CI: 36.7-51.4 %) groups (p=0.007). The 5-year overall survival rate was 61.0 % (95 % CI: 55.7-65.8 %) in the entire cohort and was poorer in patients with para-aortic involvement (52.5 %; 95 % CI: 45.1-59.3 %; p=0.002). A larger high-risk clinical target volume at least 43.5cm3 (p=0.0001), para-aortic node involvement (p=0.01), and a total treatment duration of more than 55 days (p=0.01) were associated with a higher recurrence risk.
CONCLUSION: Chemoradiotherapy followed by brachytherapy is effective and feasible for patients with node-positive cervical cancer. However, two-thirds of progressions or recurrences involved a distant event, suggesting the need to evaluate incremental systemic treatment strategies.